Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial - ASCEND-HF


Nesiritide is a recombinant intravenous (IV) formulation of human B-type natriuretic peptide (BNP). Earlier studies seemed to indicate that it was associated with increased renal failure and mortality; thus, its use was abandoned for the most part, especially in the United States. ASCEND-HF sought to compare outcomes after IV nesiritide versus placebo infusion in patients with acutely decompensated heart failure (ADHF).